1. Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
- Author
-
Rosha Babapour Mofrad, Niki S.M. Schoonenboom, Betty M. Tijms, Philip Scheltens, Pieter Jelle Visser, Wiesje M. van derFlier, and Charlotte E. Teunissen
- Subjects
Alzheimer's disease ,CSF ,Amyloid β 1‐42 ,Tau ,Clinical implementation ,Decision tree ,Neurology. Diseases of the nervous system ,RC346-429 ,Geriatrics ,RC952-954.6 - Abstract
Abstract Introduction We developed and validated a clinically applicable decision tree for the use of cerebrospinal fluid biomarkers in the diagnosis of Alzheimer's disease (AD). Methods Subjects with probable AD (n = 1004) and controls (n = 442) were included. A decision tree was modeled using Classification And Regression Tree analysis in a training cohort (AD n = 221; controls n = 221) and validated in an independent cohort (AD n = 783; controls n = 221). Diagnostic performance was compared to previously defined cutoffs (amyloid β 1‐42 < 813 pg/ml; tau>375 pg/ml). Results Two cerebrospinal fluid AD biomarker profiles were revealed: the “classical” AD biomarker profile (amyloid β 1‐42: 647‐803 pg/ml; tau >374 pg/ml) and an “atypical” AD biomarker profile with strongly decreased amyloid β 1‐42 (
- Published
- 2019
- Full Text
- View/download PDF